Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. - Wikidata - awgldk - TriplyDB

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

http://www.wikidata.org/entity/Q37328507

about

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease Heart failure with preserved ejection fraction: emerging drug strategies Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management Targeting heart failure with preserved ejection fraction: current status and future prospects Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing Understanding heart failure with preserved ejection fraction: where are we today?Biomarkers in heart failure with preserved ejection fraction Breakthrough in heart failure with preserved ejection fraction: are we there yet?Left ventricular heart failure and pulmonary hypertension Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Pulmonary hypertension: diagnostic and therapeutic challenges Myocardial hypertrophy and its role in heart failure with preserved ejection fraction An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies Therapeutic potential of PDE modulation in treating heart disease Patient selection in heart failure with preserved ejection fraction clinical trials Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure Heart failure with preserved ejection fraction The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology Male and female hypertrophic rat cardiac myocyte functional responses to ischemic stress and β-adrenergic challenge are different.Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications What global diastolic function is, what it is not, and how to measure it Diastolic dysfunction The emperor's new clothes: PDE5 and the heart Swimming-Induced Pulmonary Edema: Pathophysiology and Risk Reduction With Sildenafil.Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model Should there be sex-specific criteria for the diagnosis and treatment of heart failure?Cardiovascular Disease in Women: Clinical Perspectives.Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone.Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction.

P2860

Q24323316-7B80325F-752F-4425-BEE2-697CA8F3EB02 Q24595118-E47FD6A8-76E8-46D6-8DC5-9FD035B89713 Q26745756-131019B6-24ED-46B3-9F43-75A5D0BE563D Q26750994-9501AC95-6474-4251-98E7-177F528BEAC0 Q26752956-376E5430-9C39-4E7E-A83C-58F60FD16DA3 Q26765931-B4252D7E-DDE8-4876-B1BA-C2CF9F5B13EF Q26766355-5964B566-0491-49E6-AB17-C128654F18FC Q26766590-31F7899F-1386-4925-81CD-5219C4E23953 Q26768192-A517ADAB-BB64-466A-82A5-66004B26090D Q26771999-E806329D-9B8E-42CA-B692-A69A7A03D1DC Q26778341-D53CF528-DBAE-4595-BDB5-406DAB163EE3 Q26779538-6A3A0F03-BAD3-4A08-A263-270CB3A9B32F Q26785931-AFF422A5-4311-4587-9133-40C438917BCA Q26796434-7E54722E-6E35-4E86-8B7F-3BDE16958A77 Q26800076-7EC54B22-4033-4854-AA6A-B2CB1588A1D3 Q26829758-B0419EC0-30E0-49DA-86BC-05B3635A97FA Q26853363-941BB439-9EBB-43DF-AFDD-C39E6F12F27A Q26991985-A30D945D-6564-480A-B646-42FE3C32F1D6 Q27000263-A8EA51EF-1A25-4610-A1FE-E3D4659C558E Q27005761-DE81D9C2-9877-46D7-99F1-56B559565844 Q27015845-2A984DFE-F8B2-4D62-8494-5B1170450DD6 Q27021649-C0D2E7F5-8570-4489-A62C-1FE8247C2F72 Q27022359-C60AC2F9-DAB8-4665-BC57-FD7C3B8D2CAB Q27024008-43628B0E-E298-42F0-9DD0-2E45508943C4 Q27024279-5D959C30-65DD-4675-972F-AFEB5F00F4D9 Q27024879-3F65B99A-3123-467F-978D-F0766973EC46 Q27321564-5A215B1D-3EF2-4A4B-A0B2-7D4EA637E3A6 Q27967859-CEC8B0FA-7CDD-49EB-8D17-5C1169959866 Q28073079-DDC18CE7-D228-4905-86D5-076C6E401828 Q28085102-76895720-3137-4C0E-B229-62BEE43B4C88 Q28087043-42A244A6-8256-403E-8DA2-764B19B77093 Q28087715-3396EB7F-0053-41E2-85BA-9C35288890BC Q28543897-7362D0DC-8FE2-4D38-BBDF-2386C4CB18CF Q30277332-6BCCAFDD-DA68-4599-A3FA-1E27CD947A4F Q30385717-57B03A6F-E8DF-49E0-9182-40DB705DD19F Q30442043-FB4B4957-1A9A-4137-8F9C-77FA37EAC4B6 Q30743765-B165F4A6-2B64-4AC5-93D1-C5F49208A211 Q30833375-93921511-00F4-458D-9D21-3E7FA8C3F8AF Q33565707-44D7B41F-B748-4865-99D0-0A59F0F91C54 Q33568831-B9845481-6FB2-40F5-9C36-A05C70C13E29

P2860

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

http://www.wikidata.org/entity/Q37328507

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effect of phosphodiesterase-5 ...... : a randomized clinical trial.

@en

Effect of phosphodiesterase-5 ...... : a randomized clinical trial.

@nl

type

label

Effect of phosphodiesterase-5 ...... : a randomized clinical trial.

@en

Effect of phosphodiesterase-5 ...... : a randomized clinical trial.

@nl

prefLabel

Effect of phosphodiesterase-5 ...... : a randomized clinical trial.

@en

Effect of phosphodiesterase-5 ...... : a randomized clinical trial.

@nl

P1433

Q37328507-18D29DEE-3D61-4C43-B9D0-566700D5A6AB

P1476

Q37328507-F88E5155-65BC-42CE-A2B3-E1040C6903FA

P2093

Q37328507-00551713-815A-488E-A555-3B113C465BE7

Q37328507-06F346D2-CD05-4BE1-9799-496D766436FD

Q37328507-0BC514EE-C266-487E-A8CD-454F05A7C079

Q37328507-0C5EA0D8-6461-418D-AB0C-66155F90B86D

Q37328507-40DAF697-CB28-4636-997A-A8697522951A

Q37328507-4E1B9F39-06D2-4F41-9165-CF2F0454F8DD

Q37328507-5C197664-6574-48C2-92D0-0B276CDA6AA9

Q37328507-604F63A9-BA20-4C0E-BD65-120CC10F1D6C

Q37328507-6233B9AE-7814-43BC-A41C-B988B5CD5A20

Q37328507-6EE5066B-45F0-483C-9C1F-3A3FAC74AC7C

P2860

Q37328507-0369CDF0-E8EB-4353-90A3-3556FA7E73EC

Q37328507-122B1BB0-1090-4EE6-AC2B-25BB7FFBF4A6

Q37328507-171D6A08-0F2D-4897-AB62-11C72163AB3D

Q37328507-1C9F28CA-38C1-4EB4-93CF-E9A2950FE0EA

Q37328507-1E140760-95A1-4E96-8246-431DA9DB947C

Q37328507-3C392F14-D16C-48A0-B936-E295F98111E0

Q37328507-4198110B-624A-414E-9844-2C58CEF2C2F9

Q37328507-4209030C-BFDC-4DFE-B8C5-55A8720CEAE2

Q37328507-4971A931-8FEF-4E50-9638-151CAA8E971C

Q37328507-53E061BA-A317-4C34-9161-051754179447

P304

Q37328507-A4366975-2283-4869-A23C-D0146B410B11

P31

Q37328507-4436BC87-04B6-4DF3-9439-520CCE5EDB66

P356

Q37328507-60571B12-42C0-4EDB-80E5-45187D2CAD12

P407

Q37328507-16B7B9B7-57E8-41B1-90DC-083FFC91D878

P433

Q37328507-F6C5DE5F-377B-4597-9DA6-AC513EC2ACEC

P478

Q37328507-25C6FFE0-D552-4123-A4BD-4934849E6088

P50

Q37328507-59A51C4A-2888-45A4-AB5B-B869CD60622E

Q37328507-A0B14BFF-D7F5-4F50-A075-79EDEE5C5BA5

Q37328507-BF6E67DC-8A81-4C2B-96A7-33F5DFFB0A1E

Q37328507-CDDF4A01-BEBA-40B4-8056-AA306AA565EF

Q37328507-D6D1F64D-8F57-4C36-ABAE-CC33905A9BE8

P577

Q37328507-3DF06029-807F-4C50-B8F5-10245D45628F

P698

Q37328507-6E5A4FF4-A5FD-4582-B487-0119499CA157

P921

Q37328507-BB0233B0-C529-4EAF-91C4-D31270EF489F

P932

Q37328507-118592A1-6942-404F-933E-FBD04ABF231E

P356

P1433

Journal of the American Medical Association

P1476

Effect of phosphodiesterase-5 ...... : a randomized clinical trial.

@en

P2093

Alice M Mascette

http://www.w3.org/2001/XMLSchema#string

Anita Deswal

http://www.w3.org/2001/XMLSchema#string

Barry A Borlaug

http://www.w3.org/2001/XMLSchema#string

Bradley A Bart

http://www.w3.org/2001/XMLSchema#string

David A Bull

http://www.w3.org/2001/XMLSchema#string

Elizabeth O Ofili

http://www.w3.org/2001/XMLSchema#string

Eric J Velazquez

http://www.w3.org/2001/XMLSchema#string

G Michael Felker

http://www.w3.org/2001/XMLSchema#string

Grace Lin

http://www.w3.org/2001/XMLSchema#string

Gregory Lewis

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats

Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction

Cardiac resynchronization in chronic heart failure.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.

Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance.

Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension.

Epidemiology of diastolic heart failure.

Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

P304

1268-1277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2013.2024

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

309

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Braunwald

Adrian F. Hernandez

Douglas L. Mann

Kevin J Anstrom

Christopher M O'Connor

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23478662

http://www.w3.org/2001/XMLSchema#string

P921

P932

3835156

http://www.w3.org/2001/XMLSchema#string